| 2026-10-22 17:29 |
8-K |
["1.01"] |
other |
0.05
|
Private placement financing with convertible notes and warrants; no M&A signals detected. |
SEC · detail |
| 2026-10-19 16:05 |
8-K |
["1.01", "3.02", "9.01"] |
other |
0.08
|
Warrant waiver and issuance agreement with existing investors; routine financing matter unrelated to M&A. |
SEC · detail |
| 2026-10-13 16:45 |
8-K |
["9.01"] |
merger agreement |
0.95
|
Form 8-K/A Amendment No. 2 discloses pro forma financials for completed merger between Glucotrack and Lokahi Therapeutics. |
SEC · detail |
| 2026-09-28 17:29 |
8-K |
["1.01", "9.01"] |
other |
0.05
|
Routine financing amendments to bridge and convertible notes; no M&A signals detected. |
SEC · detail |
| 2026-09-24 17:15 |
8-K |
["1.01"] |
other |
0.05
|
Registered direct offering of common stock and pre-funded warrants; no M&A signals. |
SEC · detail |
| 2026-09-23 09:21 |
8-K |
["7.01", "9.01"] |
other |
0.15
|
8-K filing with Item 7.01 shareholder update and Rule 425 box checked; no M&A language disclosed in excerpt. |
SEC · detail |
| 2026-09-18 17:10 |
8-K |
["5.02", "9.01"] |
officer change |
0.72
|
Board member resignation citing conflict of interest related to ongoing merger agreement implementation discussions. |
SEC · detail |
| 2026-09-14 16:15 |
8-K |
["1.01", "5.07", "9.01"] |
material agreement |
0.15
|
Financing activity (ELOC, bridge notes/warrants) with stockholder approval; no M&A signals detected. |
SEC · detail |
| 2026-09-11 17:20 |
8-K |
["1.01"] |
other |
0.05
|
Private placement financing of convertible notes and warrants; no M&A or acquisition signals. |
SEC · detail |
| 2026-09-09 17:00 |
8-K |
["1.01", "2.03", "3.02"] |
other |
0.15
|
Debt settlement and restructuring with convertible note; no M&A or activist transaction signals. |
SEC · detail |
| 2026-08-28 17:15 |
8-K |
["5.03", "8.01"] |
other |
0.05
|
Reverse stock split (1-for-15) announcement with EPS restatement; no M&A signals present. |
SEC · detail |
| 2026-08-28 16:28 |
8-K |
["2.01", "9.01"] |
merger agreement |
0.95
|
Glucotrack completed reverse merger with Lokahi Therapeutics; 8-K/A Amendment filing pro forma financials and acquired company statements. |
SEC · detail |
| 2026-08-27 08:44 |
8-K |
["7.01", "9.01"] |
other |
0.05
|
Reverse stock split announcement with no M&A relevance. |
SEC · detail |
| 2026-08-19 09:00 |
8-K |
["5.07"] |
other |
0.05
|
Routine annual stockholder meeting with director elections, auditor ratification, and warrant/reverse split proposals. No M&A signal. |
SEC · detail |
| 2026-08-10 16:05 |
8-K |
["1.01", "3.02", "9.01"] |
other |
0.05
|
Amendment to equity line of credit facility; no M&A signal. |
SEC · detail |
| 2026-08-05 17:20 |
8-K |
["1.01"] |
material agreement |
0.15
|
Bridge financing follow-on investment; no M&A indicators present. |
SEC · detail |
| 2026-07-30 17:29 |
8-K |
["7.01", "9.01"] |
other |
0.45
|
8-K Item 7.01 discloses joint press release with Lokahi Therapeutics; press release not provided in excerpt. |
SEC · detail |
| 2026-07-29 17:15 |
8-K |
["1.01", "2.03", "3.02", "9.01"] |
other |
0.15
|
Debt-to-equity exchange agreement with investor; no M&A transaction indicated. |
SEC · detail |
| 2026-07-27 16:30 |
8-K |
["1.01", "2.03", "3.02", "9.01"] |
other |
0.05
|
Debt restructuring and note-to-equity conversion agreement; no M&A or acquisition signals. |
SEC · detail |
| 2026-07-15 17:20 |
8-K |
["1.01"] |
merger agreement |
0.98
|
Glucotrack (GCTK) completed merger with Lokahi Therapeutics per definitive Merger Agreement dated July 14, 2026. |
SEC · detail |
| 2026-05-15 16:45 |
8-K |
["3.01", "9.01"] |
other |
0.05
|
Nasdaq delisting notice for failing bid price and equity requirements; no M&A signal. |
SEC · detail |
| 2026-05-14 17:27 |
8-K |
["2.02", "9.01"] |
other |
0.05
|
Routine quarterly earnings announcement with no M&A indicators present. |
SEC · detail |
| 2026-05-07 16:07 |
8-K |
["7.01", "9.01"] |
other |
0.15
|
8-K filed with Items 7.01 and 9.01 referencing a press release; no M&A language visible in excerpt. |
SEC · detail |
| 2026-04-30 17:20 |
8-K |
["1.01", "2.03", "3.02", "7.01", "9.01"] |
other |
0.08
|
Debt-to-equity exchange with investor; no M&A, strategic review, or acquisition signals present. |
SEC · detail |
| 2026-04-30 09:22 |
8-K |
["7.01", "9.01"] |
other |
0.00
|
8-K with Items 7.01 and 9.01 referencing a press release; no M&A-related content disclosed. |
SEC · detail |